Endologix Hopes Nellix Deal Is A Winning Hand
Executive Summary
AAA company Endologix Inc. is carving a niche for itself in the crowded endovascular aneurysm repair field with two new products. It has developed a method of delivering aortic aneurysm grafts through a percutaneous opening, but the company’s larger opportunity might lie in a piece of technology acquired three years ago – the Nellix Endovascular Aneurysm Sealing system.
You may also be interested in...
News Briefs: Illumina Genomics Incubator; Invacare Plant Closure; New Products
Illumina launches incubator for next-gen sequencing. Invacare will close a Canada manufacturing facility. New products from Tryton, Endologix and Cook. More news.
EVAR Update: Competitors Stake Their Ground In A High-Growth Space
The endovascular abdominal aortic aneurysm repair (EVAR) market is one of the brightest growth opportunities in the medical device arena today. As a result, the competitive landscape is heating up as several new entrants stake their claim for a share of this $1+ billion opportunity.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.